Welcome to Open Science
Contact Us
Home Books Journals Submission Open Science Join Us News
Management of Treatment Resistant Depression – A Systematic Review
Current Issue
Volume 5, 2018
Issue 3 (September)
Pages: 67-71   |   Vol. 5, No. 3, September 2018   |   Follow on         
Paper in PDF Downloads: 62   Since Aug. 5, 2018 Views: 1260   Since Aug. 5, 2018
Authors
[1]
Balasubramanian Thirumalaisamy, Department of Pharmacology, Al Shifa College of Pharmacy, Kerala, India.
[2]
Lina Elizabeth Cherian, Department of Pharmacy Practice, Al Shifa College of Pharmacy, Kerala, India.
[3]
Balan Paramasivam, Department of Pharmaceutical Chemistry, Al Shifa College of Pharmacy, Kerala, India.
[4]
Jisna Jamal, Department of Pharmacy Practice, Al Shifa College of Pharmacy, Kerala, India.
[5]
Mumthas Arpurath Habeeb, Department of Pharmacy Practice, Al Shifa College of Pharmacy, Kerala, India.
[6]
Murshid Cheriyeri Peediyekal, Department of Pharmacy Practice, Al Shifa College of Pharmacy, Kerala, India.
Abstract
Treatment resistance is an emerging issue faced by physicians worldwide. Treatment resistant depression is a severely disabling disorder which affects about 30-46% of patients with major depressive disorder. Depression is defined treatment resistant in patients who failed different classes of two or more antidepressants with adequate treatment dosages and durations. The aim of this paper is to review the available management strategies of treatment resistant depression and provide an overall idea in this disease. Usual management strategies that are suggested to deal with treatment resistant depression include optimizing the existing treatment, switching to another antidepressant, augmentation strategies, combination of antidepressants, adding psychotherapy and ECT and other non-pharmacologic therapies.
Keywords
Treatment Resistance Depression, Antidepressants, Pharmacological Management
Reference
[1]
Noah S. Philip, Linda L. Carpenter, Audrey R. Tyrka, Lawrence H. Price. Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. Expert Opinion on Pharmacotherapy. 2010; 11: 709–722.
[2]
Khalid Saad Al-Harbi. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Preference and Adherence. 2012; 6: 369–388.
[3]
Chien-Han Lai. Mirtazapine and bupropion combined treatment in treatment-resistant depression. Tzu Chi Medical Journal. 2009; 21: 352-354.
[4]
Sakina J Rizvi, Etienne Grima, Mary Tan, Susan Rotzinger, Peter Lin, Roger S McIntyre, et al. Treatment-resistant depression in primary care across Canada. The Canadian Journal of Psychiatry. 2014; 59: 349-357.
[5]
Yiru Fang, MD, Chengmei Yuan, Yifeng Xu, Jun Chen, Zhiguo Wu, Lan Cao, et al. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression. Journal of Clinical Psychopharmacology. 2010; 30: 357-364.
[6]
Jerald Kay, Rafay Atiq. Treatment-Resistant Depression. www.turner-white.com. Psychiatry. 2006; 10: 1-11.
[7]
Ruhe HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. Journal of Clinical Psychiatry. 2006; 67: 1836–1855.
[8]
Vieta E, Colom F. Therapeutic options in treatment-resistant depression. Annals of Medicine. 2011; 43: 512–530.
[9]
Bschor T, Bauer M. Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Current Pharmaceutical Design. 2006; 12: 2985–2992.
[10]
Martín-López LM, Rojo JE, Gibert K, et al. The strategy of combining antidepressants in the treatment of major depression: clinical experience in Spanish outpatients. Depress Research and Treatment. 2011; 2011: 140-194.
[11]
Alison Little. Treatment-resistant depression. American Family Physician. 2009; 80: 167-172.
[12]
Triezenberg D, Vachon D, Helmen J, Schneider D. Clinical inquiries: how should you manage a depressed patient unresponsive to an SSRI? Journal of Family Practice. 2006; 55: 1081–1087.
[13]
Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. New England Journal of Medicine. 2000; 342: 1462–1470.
[14]
Khalid N, Atkins M, Tredget J, Giles M, Champney-Smith K, Kirov G. The effectiveness of electroconvulsive therapy in treatment-resistant depression: a naturalistic study. Journal of Electroconvulsive Therapy. 2008; 24: 141–145.
[15]
Hoy KE, Fitzgerald PB. Magnetic seizure therapy for treatment resistant depression. Expert Review of Medical Devices. 2011; 8: 723–732.
[16]
Cusin C, Dougherty DD. Somatic therapies for treatment-resistant depression: ECT, TMS, VNS, DBS. Biology of Mood and Anxiety Disorders. 2012; 2: 14.
[17]
Mansoor Ahmad Dar, Rayees Ahmad Wani, Mushtaq Ahmad Margoob, InInaamul Haq, Rshad Hussain, Rajesh Kumar Chandel, Yasir Hassan Rather, MajidShafi Shah, Altaf Ahmad Malla, Role of Amisulpride Augmentation in Treatment Resistant Major Depressive Disorder: An Open Label Study from North India. International Journal of Emergency Mental Health and Human Resilience, 2015, 17 (2), 538-543.
[18]
Mark Hyman Rapaport, Georges M Gharabawi, Carla M Canuso, Ramy A Mahmoud, Martin B Keller, Cynthia A Bossie, Ibrahim Turkoz, Robert A Lasser, Amy Loescher, Philippe Bouhours, Fiona Dunbar & Charles B Nemeroff. Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Fol lowed by Double-Blind Continuation. Neuropsychopharmacology, 2006, 31 (11); 2505–2513.
[19]
Tracy L. Greer, Prabha Sunderajan, Bruce D. Grannemann, Madhukar H. Trivedi. Cognitive and Psychosocial Improvements Following Aripiprazole Augmentation of SSRI Antidepressant Therapy in Treatment Refractory Depression: A Pilot Study SciRes Open Journal of Depression. 2013; 02 (04): 45-53.
[20]
Noel Kennedy and Michael McDonough. Pharmacological management of treatment resistant depression: A clinical review. Irish Journal of Psychological Medicine, 2003, 20 (1). 18-23.
[21]
Li X, Xing B, Yu E, Chen W, Wu H. The combined treatment of venlafaxine and quetiapine for treatment-resistant depression: a clinical study. Journal of Neuropsychiatry and Clinical Neurosciences. 2013; 25 (2): 157-160.
[22]
Xiaomei Zhong, Hongbo He, Chunping Zhang, Zhijie Wang, Miaoling Jiang, Qirong Li, Minling Zhang, Xiong Huang. Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment resistant depression. Journal of Affective Disorders. 2016; 201: 124-130.
[23]
Trevino K, McClintock SM, McDonald Fischer N, Vora A, Husain MM. Defining treatment-resistant depression: a comprehensive review of the literature. Annals of Clinical Psychiatry. 2014; 26 (3): 222-232.
[24]
Dawn F. Ionescu. Pharmacological approaches to the challenge of reatment resistant depression. 2015; Dialogues Clinical Neuroscience. 2015; 17 (2): 111–126.
Open Science Scholarly Journals
Open Science is a peer-reviewed platform, the journals of which cover a wide range of academic disciplines and serve the world's research and scholarly communities. Upon acceptance, Open Science Journals will be immediately and permanently free for everyone to read and download.
CONTACT US
Office Address:
228 Park Ave., S#45956, New York, NY 10003
Phone: +(001)(347)535 0661
E-mail:
LET'S GET IN TOUCH
Name
E-mail
Subject
Message
SEND MASSAGE
Copyright © 2013-, Open Science Publishers - All Rights Reserved